Depersonalization

ESRT-2 significantly reduced depersonalization in mixed-specialty PGY-1 residents compared to active controls at 32-week follow-up, with a medium effect size, though not at post-intervention.

Effect: improvement; Cohen d = 0.69 (32-wk)

ESRT-2 significantly reduced depersonalization in mixed-specialty PGY-1 residents compared to active controls at 32-week follow-up, with a medium effect size, though not at post-intervention.

Effect: improvement; Cohen d = 0.69 (32-wk)

ESRT-2 significantly reduced depersonalization in mixed-specialty PGY-1 residents compared to active controls at 32-week follow-up, with a medium effect size, though not at post-intervention.

Effect: improvement; Cohen d = 0.69 (32-wk)

ESRT-2 significantly reduced depersonalization in mixed-specialty PGY-1 residents compared to active controls at 32-week follow-up, with a medium effect size, though not at post-intervention.

Effect: improvement; Cohen d = 0.69 (32-wk)

ESRT-2 significantly reduced depersonalization in mixed-specialty PGY-1 residents compared to active controls at 32-week follow-up, with a medium effect size, though not at post-intervention.

Effect: improvement; Cohen d = 0.69 (32-wk)

ESRT-2 significantly reduced depersonalization in mixed-specialty PGY-1 residents compared to active controls at 32-week follow-up, with a medium effect size, though not at post-intervention.

Effect: improvement; Cohen d = 0.69 (32-wk)

ESRT-2 significantly reduced depersonalization in mixed-specialty PGY-1 residents compared to active controls at 32-week follow-up, with a medium effect size, though not at post-intervention.

Effect: improvement; Cohen d = 0.69 (32-wk)

ESRT-2 significantly reduced depersonalization in mixed-specialty PGY-1 residents compared to active controls at 32-week follow-up, with a medium effect size, though not at post-intervention.

Effect: improvement; Cohen d = 0.69 (32-wk)

ESRT-2 significantly reduced depersonalization in mixed-specialty PGY-1 residents compared to active controls at 32-week follow-up, with a medium effect size, though not at post-intervention.

Effect: improvement; Cohen d = 0.69 (32-wk)

ESRT-2 significantly reduced depersonalization in mixed-specialty PGY-1 residents compared to active controls at 32-week follow-up, with a medium effect size, though not at post-intervention.

Effect: improvement; Cohen d = 0.69 (32-wk)

ESRT-2 significantly reduced depersonalization in mixed-specialty PGY-1 residents compared to active controls at 32-week follow-up, with a medium effect size, though not at post-intervention.

Effect: improvement; Cohen d = 0.69 (32-wk)

ESRT-2 significantly reduced depersonalization in mixed-specialty PGY-1 residents compared to active controls at 32-week follow-up, with a medium effect size, though not at post-intervention.

Effect: improvement; Cohen d = 0.69 (32-wk)

ESRT-2 significantly reduced depersonalization in mixed-specialty PGY-1 residents compared to active controls at 32-week follow-up, with a medium effect size, though not at post-intervention.

Effect: improvement; Cohen d = 0.69 (32-wk)

ESRT-2 significantly reduced depersonalization in mixed-specialty PGY-1 residents compared to active controls at 32-week follow-up, with a medium effect size, though not at post-intervention.

Effect: improvement; Cohen d = 0.69 (32-wk)

ESRT-2 significantly reduced depersonalization in mixed-specialty PGY-1 residents compared to active controls at 32-week follow-up, with a medium effect size, though not at post-intervention.

Effect: improvement; Cohen d = 0.69 (32-wk)

ESRT-2 significantly reduced depersonalization in mixed-specialty PGY-1 residents compared to active controls at 32-week follow-up, with a medium effect size, though not at post-intervention.

Effect: improvement; Cohen d = 0.69 (32-wk)

ESRT-2 significantly reduced depersonalization in mixed-specialty PGY-1 residents compared to active controls at 32-week follow-up, with a medium effect size, though not at post-intervention.

Effect: improvement; Cohen d = 0.69 (32-wk)

ESRT-2 significantly reduced depersonalization in mixed-specialty PGY-1 residents compared to active controls at 32-week follow-up, with a medium effect size, though not at post-intervention.

Effect: improvement; Cohen d = 0.69 (32-wk)

ESRT-2 significantly reduced depersonalization in mixed-specialty PGY-1 residents compared to active controls at 32-week follow-up, with a medium effect size, though not at post-intervention.

Effect: improvement; Cohen d = 0.69 (32-wk)

ESRT-2 significantly reduced depersonalization in mixed-specialty PGY-1 residents compared to active controls at 32-week follow-up, with a medium effect size, though not at post-intervention.

Effect: improvement; Cohen d = 0.69 (32-wk)

ESRT-2 significantly reduced depersonalization in mixed-specialty PGY-1 residents compared to active controls at 32-week follow-up, with a medium effect size, though not at post-intervention.

Effect: improvement; Cohen d = 0.69 (32-wk)

ESRT-2 significantly reduced depersonalization in mixed-specialty PGY-1 residents compared to active controls at 32-week follow-up, with a medium effect size, though not at post-intervention.

Effect: improvement; Cohen d = 0.69 (32-wk)

ESRT-2 significantly reduced depersonalization in mixed-specialty PGY-1 residents compared to active controls at 32-week follow-up, with a medium effect size, though not at post-intervention.

Effect: improvement; Cohen d = 0.69 (32-wk)

ESRT-2 significantly reduced depersonalization in mixed-specialty PGY-1 residents compared to active controls at 32-week follow-up, with a medium effect size, though not at post-intervention.

Effect: improvement; Cohen d = 0.69 (32-wk)

ESRT-2 significantly reduced depersonalization in mixed-specialty PGY-1 residents compared to active controls at 32-week follow-up, with a medium effect size, though not at post-intervention.

Effect: improvement; Cohen d = 0.69 (32-wk)

ESRT-2 significantly reduced depersonalization in mixed-specialty PGY-1 residents compared to active controls at 32-week follow-up, with a medium effect size, though not at post-intervention.

Effect: improvement; Cohen d = 0.69 (32-wk)

ESRT-2 significantly reduced depersonalization in mixed-specialty PGY-1 residents compared to active controls at 32-week follow-up, with a medium effect size, though not at post-intervention.

Effect: improvement; Cohen d = 0.69 (32-wk)